Endocrine Markers of Cancer
Endocrine Markers of Cancer
复制标题
癌症的内分泌标志物
DOI:
10.1007/978-1-4612-5808-7_14
复制
发表时间:
1982
影响因子:
2.7
通讯作者:
S. Baylin
中科院分区:
文献类型:
--
作者:
G. Mendelsohn;S. Baylin
Specific “endocrine” markers (polypeptide hormones and biogenic amines) have for several decades now played a vital role in the clinical evaluation and management of patients with a wide range of endocrine tumors. Some of these hormones, such as ACTH, gastrin, insulin, vasoactive intestinal peptide (VIP), and serotonin are responsible for the production of specific and often dramatic clinical syndromes. Others, such as calcitonin, a highly sensitive marker for the spectrum of thyroid C-cell proliferative disorders, are not associated with any known clinical syndromes. Ectopic (inappropriate) endocrine syndromes in patients with non- endocrine tumors have likewise been recognized for several decades. The earliest appreciation of inappropriate endocrine activity by tumors dates back to the 1920s (Klemperer, 1923; Brown, 1928), and over the ensuing years, numerous examples of inappropriate endocrine syndromes have been noted in patients with non-endocrine tumors (Meador et al., 1962; Lipsett et al., 1964; Liddle et al., 1969; And erson, 1973; Ratcliff and Rees, 1974; Blackman et al., 1978; Trump and Baylin, 1979). In 1948, it was first appreciated that humoral factors might be involved in these endocrine syndromes (Albright and Reifenstein, 1948).
影响因子:
20.3
作者:
Baylin,SB;Mendelsohn,G
通讯作者:
Mendelsohn,G
DOI:
10.1016/0736-5748(89)90063-4
发表时间:
1989
期刊:
International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience
影响因子:
--
作者:
Reynolds,CP;Perez-Polo,JR
通讯作者:
Perez-Polo,JR
影响因子:
20.3
作者:
Eipper,BA;Mains,RE
通讯作者:
Mains,RE